In situ click chemistry generation of cyclooxygenase-2 inhibitors. [PDF]
Nat Commun, 2017 Bhardwaj A, Kaur J, Wuest M, Wuest F.
europepmc +1 more source
Antitumor Activity of Cytotoxic Cyclooxygenase-2 Inhibitors. [PDF]
ACS Chem Biol, 2016 Uddin MJ +7 more
europepmc +1 more source
Cardiovascular effects of cyclooxygenase-2 inhibitors: a mechanistic and clinical perspective. [PDF]
Br J Clin Pharmacol, 2016 Patrono C.
europepmc +1 more source
Structure-activity relationships for the synthesis of selective cyclooxygenase 2 inhibitors: an overview (2009-2016). [PDF]
Medchemcomm, 2017 Carullo G, Galligano F, Aiello F.
europepmc +1 more source
Use of Selective Cyclooxygenase-2 Inhibitors, Other Analgesics, and Risk of Glioma. [PDF]
PLoS One, 2016 Seliger C +6 more
europepmc +1 more source
Propyphenazone-based analogues as prodrugs and selective cyclooxygenase-2 inhibitors. [PDF]
ACS Med Chem Lett, 2014 Radwan MF, Dalby KN, Kaoud TS.
europepmc +1 more source
Cardiovascular and cerebrovascular risk with nonsteroidal anti-inflammatory drugs and cyclooxygenase 2 inhibitors: latest evidence and clinical implications. [PDF]
Ther Adv Drug Saf, 2017 Fanelli A, Ghisi D, Aprile PL, Lapi F.
europepmc +1 more source
Comparison of benefit-risk preferences of patients and physicians regarding cyclooxygenase-2 inhibitors using discrete choice experiments. [PDF]
Patient Prefer Adherence, 2016 Byun JH +5 more
europepmc +1 more source
Tolerability of selective cyclooxygenase 2 inhibitors used for the treatment of rheumatological manifestations of inflammatory bowel disease. [PDF]
Cochrane Database Syst Rev, 2014 Miao XP +5 more
europepmc +1 more source
Clinical Profile of Cyclooxygenase-2 Inhibitors in Treating Non-Small Cell Lung Cancer: A Meta-Analysis of Nine Randomized Clinical Trials. [PDF]
PLoS One, 2016 Zhou YY, Hu ZG, Zeng FJ, Han J.
europepmc +1 more source